Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
Cash from Financing Activities
Antengene Corporation Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Cash from Financing Activities
¥131.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Financing Activities
-¥4.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Cash from Financing Activities
-¥1.3B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-20%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Financing Activities
-¥1.6B
|
CAGR 3-Years
-84%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-105%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Financing Activities
-¥3.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-24%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Cash from Financing Activities
-¥611.5m
|
CAGR 3-Years
-143%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Cash from Financing Activities?
Cash from Financing Activities
131.8m
CNY
Based on the financial report for Dec 31, 2024, Antengene Corporation Ltd's Cash from Financing Activities amounts to 131.8m CNY.
What is Antengene Corporation Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-30%
Over the last year, the Cash from Financing Activities growth was 0%.
You don't have any saved screeners yet